Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoB-Cap1: [177Lu]Lu-NeoB + Capecitabine in ER+/HER2- Metastatic Breast Cancer
NCT06247995Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Peptides
- Countries
- 13
01
Overview
A Phase 2 trial of AAA503 in breast cancer, sponsored by Novartis. Started Aug 2024; status: active, not recruiting.
02
Drugs
AAA503
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06247995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247995.